Search

Displaying results 2271 - 2280 of 5302 in total
  1. Drug

    Lymecycline

    go.drugbank.com/drugs/DB00256
    ApprovedInvestigationalWithdrawn

    Lymecycline is a broad-spectrum second-generation tetracycline antibiotic used for the treatment of acne and other susceptible bacterial infections. It has been proven a cost-effective alternative to treatment with minocycline with compa...

  2. Drug

    Theobromine

    go.drugbank.com/drugs/DB01412
    Investigational

    (From Martindale, The Extra Pharmacopoeia, 30th ed, pp1318-9)

  3. Drug

    EW-A-401

    go.drugbank.com/drugs/DB05525
    Investigational

    EW-A-401 is a circle of genetic material (plasmid DNA) that instructs the body to produce a genetically-engineered transcription factor, a protein that regulates expression of genes.

    Synonyms: EW-A-401 DNA Plasmid Vector
  4. Drug

    Diphenoxylate

    go.drugbank.com/drugs/DB01081
    ApprovedIllicitInvestigational

    A meperidine congener used as an antidiarrheal, usually in combination with atropine. At high doses, it acts like morphine.

  5. Drug

    Rheinanthrone

    go.drugbank.com/drugs/DB13175
    Experimental

    Rheinanthrone is the active metabolite of senna glycoside DB11365 known for its laxative effect . It is commonly produced by plants of the Rheum species .

  6. Drug

    Fludeoxyglucose (18F)

    go.drugbank.com/drugs/DB09502
    ApprovedInvestigational

    Fludeoxyglucose F 18 Injection is a positron emitting radiopharmaceutical containing no-carrier added radioactive 2-deoxy-2-[18F]fluoro-D-g1ucose, which is used for diagnostic purposes in conjunction with Positron Emission Tomography (PE...

  7. Drug

    Roxadustat

    go.drugbank.com/drugs/DB04847
    ApprovedInvestigational

    [A245393] Roxadustat was first approved by the European Commission in August 2021.[L40323]

  8. Drug

    Pariglasgene brecaparvovec

    go.drugbank.com/drugs/DB16801
    Approved

    Pariglasgene brecaparvovec-opnr is an adeno-associated virus serotype 8 (AAV8)–based gene therapy for glycogen storage disease type Ia (GSDIa), a disorder caused by deficiency of the enzyme glucose-6-phosphatase

  9. Drug

    Sofosbuvir

    go.drugbank.com/drugs/DB08934
    ApprovedInvestigational

    This is an important advantage relative to HCV drugs that target other viral enzymes such as the protease, for which rapid development of resistance has proven to be an important cause of therapeutic failure … With the price per pill set at $1000, a 12-week treatment can cost upwards of $84,000 per patient [A19636].

  10. Drug

    Bromotheophylline

    go.drugbank.com/drugs/DB14018
    Approved

    [A33018] Bromotheophylline is categorized on the FDA as a drug substance with an inactive state since March, 1980.